Vir Biotechnology’s (VIR) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Vir Biotechnology (NASDAQ:VIR) in a report released on Monday morning,Benzinga reports. HC Wainwright currently has a $22.00 target price on the stock. HC Wainwright also issued estimates for Vir Biotechnology’s Q4 2026 earnings at ($0.09) EPS, FY2026 earnings at ($0.89) EPS, Q1 2027 earnings at ($0.46) EPS, Q2 2027 earnings at ($0.58) EPS, Q3 2027 earnings at ($0.49) EPS, Q4 2027 earnings at ($0.46) EPS and FY2027 earnings at ($1.99) EPS.

Several other equities research analysts also recently commented on VIR. Raymond James Financial reiterated a “strong-buy” rating on shares of Vir Biotechnology in a research note on Monday, September 28th. Zacks Research raised Vir Biotechnology from a “strong sell” rating to a “hold” rating in a research report on Wednesday, November 4th. Needham & Company LLC boosted their price target on Vir Biotechnology from $18.00 to $20.00 and gave the company a “buy” rating in a research note on Thursday, November 5th. Morgan Stanley set a $25.00 price target on Vir Biotechnology in a research note on Thursday, August 6th. Finally, Wall Street Zen raised Vir Biotechnology from a “hold” rating to a “buy” rating in a report on Saturday, November 7th. One investment analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $22.57.

Vir Biotechnology Stock Down 0.2%

NASDAQ:VIR opened at $13.13 on Monday. Vir Biotechnology has a 52 week low of $5.32 and a 52 week high of $14.38. The firm has a 50 day moving average of $11.16 and a 200 day moving average of $9.71. The stock has a market capitalization of $2.25 billion, a price-to-earnings ratio of -10.42 and a beta of 1.70.

Vir Biotechnology (NASDAQ:VIR) last issued its quarterly earnings results on Wednesday, November 4th. The company reported ($0.57) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.75) by $0.18. The business had revenue of ($0.19) million for the quarter, compared to analyst estimates of $0.98 million. During the same period in the previous year, the company posted ($1.17) earnings per share. The business’s revenue for the quarter was down 178.3% on a year-over-year basis. As a group, analysts expect that Vir Biotechnology will post -1.28 EPS for the current year.

Insider Activity at Vir Biotechnology

In related news, EVP Vanina de Verneuil sold 2,407 shares of Vir Biotechnology stock in a transaction dated Tuesday, November 3rd. The stock was sold at an average price of $11.10, for a total value of $26,717.70. Following the completion of the transaction, the executive vice president owned 110,193 shares in the company, valued at $1,223,142.30. The trade was a 2.14% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 2.90% of the stock is owned by company insiders.

Hedge Funds Weigh In On Vir Biotechnology

Hedge funds have recently bought and sold shares of the business. ADAR1 Capital Management LLC acquired a new stake in Vir Biotechnology in the 2nd quarter valued at $25,034,000. Parkman Healthcare Partners LLC purchased a new stake in Vir Biotechnology in the 2nd quarter worth $4,843,000. ARCH Venture Management LLC acquired a new position in Vir Biotechnology during the second quarter worth $129,353,521. Candriam S.C.A. raised its position in Vir Biotechnology by 10.1% during the first quarter. Candriam S.C.A. now owns 1,135,763 shares of the company’s stock worth $10,176,000 after acquiring an additional 104,100 shares during the period. Finally, BlackRock Inc. acquired a new position in Vir Biotechnology during the second quarter worth $210,712,000. Hedge funds and other institutional investors own 65.32% of the company’s stock.

Latest Vir Biotechnology News

Investors following VIR have been watching these news items:

• Positive Sentiment: Evercore ISI and TD Cowen reiterated Buy ratings. HC Wainwright also maintains a Buy rating and $22 price target; its updated estimates generally project narrower losses, including a smaller expected FY2027 loss. Evercore ISI rating TD Cowen rating HC Wainwright rating
• Neutral Sentiment: One article considers whether VIR remains attractively valued after a reported 127% run, reflecting debate about how much of the positive outlook is already priced in. Valuation discussion
• Negative Sentiment: The sharp prior rally may leave the stock vulnerable if expectations for Vir’s clinical pipeline or future financial performance are not met; the company is still expected to report losses.

Vir Biotechnology Company Profile

Vir Biotechnology is a clinical-stage biopharmaceutical company focused on developing treatments for infectious diseases and cancer. Its research draws on immunology and includes approaches such as monoclonal antibodies, small-interfering RNA therapies and T-cell-based treatments. The company’s pipeline has included programs targeting chronic hepatitis B and influenza, as well as investigational cancer therapies. Vir has also pursued research and development collaborations to advance its programs.